Yale Cancer Center

Exercise oncology is not just good for patients, it may be a smart investment. A team from Yale completed a cost-effectiveness analysis of the #CHALLENGEtrial + demonstrated the economic viability of reimbursing supervised exercise for patients with #coloncancer in the US. ascopubs.org/doi/pdf/10.1200… @SmilowCancer @GeorgeGoshuaMD @JCOOP_ASCO @ammanuelstaye @ManrajSra @SatokoItoMDPhD

Last week, Drs. @maryam_lustberg and Mary Jane Minkin @YaleObGynRes joined colleagues at the 'Managing Menopause After Breast Cancer' program at the #OncoMenopause Consortium in San Diego. @SmilowCancer @YaleBreast

Why are #NOTCH1 mutations common in normal esophageal tissue, but less frequent in esophageal cancer? New research from @JeffTownsend reveals that cancer-associated mutations can have different effects depending on when they arise and which other mutations are present. These stage-specific evolutionary dynamics could help identify when targeted interventions may be most effective. medicine.yale.edu/cancer/pub… @SmilowCancer @GenomeMedicine @OncoAlert @YaleSPH

.@maryam_lustberg presented on supportive and palliative care in a Scientific Congress Highlights 2 session this morning at #ESMO26. cslide.ctimeetingtech.com/es… @myESMO @SmilowCancer @YaleBreast

Please join us for #GrandRounds today at 12pm as @TranMDPhD and @ishizukalab share presentations on #melanoma and #merkelcellcarcinoma. Join us in-person at Smilow Auditorium or online via Zoom: bit.ly/4zW8SLh. @SmilowCancer @YNHH

A new @cell_res highlight from @samirzaidi + @SawyersLabMSKCC explores how next-gen, patient-derived #cancer models are expanding the Cancer Dependency Map #DepMap, revealing new therapeutic opportunities while underscoring the importance of tumor context and model fidelity. nature.com/articles/s41422-0… @SmilowCancer @MSKCancerCenter

New study results from @Cecchini_OncMD show Telisotuzumab adizutecan + bevacizumab appeared to improve efficacy outcomes with a manageable safety profile in patients with advanced #colorectalcancer, and the regimen is currently being evaluated in a Phase III trial, AndroMETa-560. #ESMO26 annalsofoncology.org/article… @SmilowCancer @myESMO @YaleGICancers @OncoAlert @Annals_Oncology

Today at #ESMO26, @maryam_lustberg presents 'Review of the development of a new cryocompression medical device for the management of CIPN in chemotherapy settings' in an EONS Satellite Symposium. #Paxman cslide.ctimeetingtech.com/es… @SmilowCancer @YaleBreast @myESMO

Monday morning at #ESMO26, @Annechiangmd presents data on ABBV-706 monotherapy showing promising clinical benefit in heavily pretreated R/R small cell lung cancer. #SCLC cslide.ctimeetingtech.com/es… @myESMO @SmilowCancer @YaleThoracic

Breast Medical Oncologist, @maryam_lustberg, is tonight’s guest on #YaleCancerAnswers, where she and host @DrEricWiner discuss a range of topics for #BreastCancerAwarenessMonth: ➡️approaches to #breastcancer, new treatments, antibody drug conjugates (ADCs) and more. 🎧Listen live tonight at 7:30pm: @wnpr 💻Listen later: @ApplePodcasts | @Spotify | @YouTube @SmilowCancer @YaleBreast

Sunday morning at #ESMO26, @BraunMDPhD presents on vaccines during a special symposium on renal cell carcinoma. #RCC cslide.ctimeetingtech.com/es… @myESMO @SmilowCancer

Today at #ESMO26, @Cecchini_OncMD presents a rapid oral presentation on updated results of a combination therapy vs. SOC study in patients with 3L+ #colorectalcancer. cslide.ctimeetingtech.com/es… @myESMO @SmilowCancer @YaleGICancers

.@sundar__raghav presents 'Challenges in biomarker testing' in an educational session Saturday morning at #ESMO26. cslide.ctimeetingtech.com/es… @myESMO @SmilowCancer @YaleGICancers

We’re excited to join oncology colleagues from around the world at #ESMO26 to share knowledge, exchange ideas, and explore the future of cancer care. We’re proud of our faculty presenting their research and look forward to engaging with the latest advances in #cancerresearch, treatment, and care. @myESMO @SmilowCancer @YNHH

New research led by @DanielPetrylak shows that #Bavdegalutamide, a novel #PROTAC cancer drug developed from research led by @CraigMCrews, may benefit patients with #mCRPC whose tumors harbor AR T878/H875 mutations, underscoring the importance of genomic testing to guide targeted treatment. medicine.yale.edu/cancer/pub… @SmilowCancer @Yale_Urology @JCO_ASCO

We are pleased to co-host the "Future of Oncology Summit" alongside @BioCT_org November 9–10 at 101 College Street, New Haven. The summit will gather leaders in oncology and healthcare from across #Connecticut and the US to explore innovative approaches to improving patient outcomes. Yale participation includes: Co-Chair & presenter @DrEricWiner; @SanjayAnejaMD; @ranjitbindra; Sarah Goldberg; Ian Krop; Patricia LoRusso; @WilliamOhMD; @DanielPetrylak; and Katerina Politi. ➡️futureofoncology2026.org/ @SmilowCancer

The #FDA approval of Veppanu marks a milestone for “protein degraders”—a promising new class of drugs designed to eliminate disease-driving proteins that have long been difficult to target. Yale scientist @CraigMCrews says the approval “will change how the industry views what is potentially druggable.” wsj.com/health/pharma/big-ph… @SmilowCancer @MCDB_Yale

Congratulations to @MuzumdarLab and @SStevenWang, recipients of an @theNCI #R33 award, which they will use to develop #RAEFISH, an innovative spatial transcriptomics technology. medicine.yale.edu/cancer/new… @SmilowCancer @YaleGenetics

CAR-T cell therapy, approved to treat some #bloodcancers, is now being studied for lupus, multiple sclerosis, and scleroderma. @MichaelEHurwitz: “CAR-T therapy is what we call a living drug. When it works well, those cells don’t just attack their target once, they expand, persist, and continue functioning in the body.” ➡️Learn more about how it works, its risks, and who can benefit: medicine.yale.edu/cancer/new… @SmilowCancer @YaleHematology @OncoAlert